From the Journals

Tool Can Help Predict Futile Surgery in Pancreatic Cancer


 

SOURCE:

This study, led by Stefano Crippa, MD, PhD, Division of Pancreatic Surgery, Pancreas Translational and Clinical Research Center, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy, and the accompanying commentary were published online in JAMA Surgery.

LIMITATIONS:

In addition to the limitations noted by the editorialists, others include the study’s retrospective design, which could introduce bias. Because preoperative imaging was not revised, the assigned resectability classes could show variability. Institutional differences existed in the selection process for upfront pancreatectomy. The model cannot be applied to cancer antigen 19.9 nonsecretors and was not externally validated.

DISCLOSURES:

The Italian Association for Cancer Research Special Program in Metastatic Disease and Italian Ministry of Health/Italian Foundation for the Research of Pancreatic Diseases supported the study in the form of a grant. Two authors reported receiving personal fees outside the submitted work. No other disclosures were reported.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

How Aspirin May Lower Risk for Colorectal Cancer
AVAHO
Factors Linked to Complete Response, Survival in Pancreatic Cancer
AVAHO
Does Extended Postop Follow-Up Improve Survival in Gastric Cancer?
AVAHO
Targeted Pancreatic Cancer Screening May Save Lives
AVAHO
‘Chemoresistance Can Be Reversed’: Toughest Cancers Targeted
AVAHO
Is Immunotherapy Best for Unresectable HCC with Moderate Liver Dysfunction?
AVAHO
Breakthrough Blood Test for Colorectal Cancer Gets Green Light
AVAHO
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
AVAHO
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer Care
AVAHO
FDA Approves First Engineered Cell Therapy for a Solid Tumor
AVAHO